Concurrent radiochemotherapy in advanced hypopharyngeal cancer
- PMID: 20482772
- PMCID: PMC2890021
- DOI: 10.1186/1748-717X-5-39
Concurrent radiochemotherapy in advanced hypopharyngeal cancer
Abstract
Background: Concurrent platinum-based radiochemotherapy has been recommended as a standard of care in patients with locally advanced squamous cell head and neck carcinomas. Unfortunately, there is a lack of level one evidence on best treatment approach for advanced hypopharyngeal cancer. This report aims to summarize the results of our study on concurrent radiochemotherapy in patients with advanced hypopharyngeal cancer.
Methods: A retrospective analysis of 41 patients with stage III-IV hypopharyngeal cancer was performed. All patients were treated with three dimensional conformal radiotherapy and received 70 Gy in 35 fractions (2 Gy per fraction, 5 fractions per week). In dependence of the period when radiotherapy was realized, two different treatment techniques were used. Concurrent chemotherapy consisted of cisplatin 30 mg/m2 given on a weekly basis.
Results: The median age was 52 years (range 29-70). Stage IV disease was recognized in 73.2% of the patients. Complete response rates at the primary site and at the metastatic neck lymph nodes were 68.3% and 36.6%, respectively. A complete composite response was present in 27 patients (65.9%). Median follow-up was 13 months (range 7-36). Distant metastases as initial failure occurred in 7 patients (46.7%). The 2-year local relapse-free survival and regional relapse-free survival rates were 55.2% and 75.8%, respectively. The 2-year locoregional relapse-free survival rate was 51.3%. The 2-year disease-free survival and overall survival rates were 29.3% and 32.8%, respectively. Confluent mucositis was developed in 46.3% of patients. Leucopenia grade 1 was the most frequent hematological toxicity. The median weight loss at the end of treatment was 12% (range 5-21). The worst grade of late toxicity was most commonly pronounced in the skin and in the subcutaneous tissue.
Conclusions: Based on unsatisfactory results in our study we suggest that the use of sequential radiochemotherapy or chemotherapy given concomitantly with altered fractionation radiotherapy with the implementation of intensity-modulated radiotherapy as radiotherapy technique could represent treatment approaches able to improve outcome in patients with advanced hypopharyngeal cancer.
Figures
Similar articles
-
Aggressive simultaneous radiochemotherapy with cisplatin and paclitaxel in combination with accelerated hyperfractionated radiotherapy in locally advanced head and neck tumors. Results of a phase I-II trial.Strahlenther Onkol. 2003 Oct;179(10):673-81. doi: 10.1007/s00066-003-1106-0. Strahlenther Onkol. 2003. PMID: 14566475 Clinical Trial.
-
Concurrent radiochemotherapy in locally-regionally advanced oropharyngeal squamous cell carcinoma: analysis of treatment results and prognostic factors.Radiat Oncol. 2012 May 28;7:78. doi: 10.1186/1748-717X-7-78. Radiat Oncol. 2012. PMID: 22640662 Free PMC article.
-
[SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].Otolaryngol Pol. 2011 Sep;65(5 Suppl):117-25. doi: 10.1016/S0030-6657(11)70719-3. Otolaryngol Pol. 2011. PMID: 22000261 Polish.
-
Hyperfractionated radiotherapy with concurrent chemotherapy for para-aortic lymph node recurrence in carcinoma of the cervix.Int J Radiat Oncol Biol Phys. 2003 Apr 1;55(5):1247-53. doi: 10.1016/s0360-3016(02)04401-2. Int J Radiat Oncol Biol Phys. 2003. PMID: 12654434 Review.
-
Radiotherapy and chemotherapy in locally advanced non-small cell lung cancer: preclinical and early clinical data.Hematol Oncol Clin North Am. 2004 Feb;18(1):41-53. doi: 10.1016/s0889-8588(03)00138-2. Hematol Oncol Clin North Am. 2004. PMID: 15005280 Review.
Cited by
-
Gemcitabine-based induction chemotherapy and concurrent with radiation in advanced head and neck cancer.Med Oncol. 2012 Dec;29(5):3367-73. doi: 10.1007/s12032-012-0269-x. Epub 2012 Jun 8. Med Oncol. 2012. PMID: 22678924 Clinical Trial.
-
Comparison between open partial laryngectomy with tube-free tracheostomy and total laryngectomy for hypopharyngeal cancer with cartilage invasion.Oncol Lett. 2018 Oct;16(4):4961-4969. doi: 10.3892/ol.2018.9298. Epub 2018 Aug 13. Oncol Lett. 2018. PMID: 30250561 Free PMC article.
-
A Novel Survival Prediction Nomogram Based on the Naples Prognostic Score and Clinicopathological Factors for Postoperative Hypopharyngeal Squamous Cell Carcinoma Patients.J Inflamm Res. 2025 Jun 5;18:7243-7262. doi: 10.2147/JIR.S521901. eCollection 2025. J Inflamm Res. 2025. PMID: 40491785 Free PMC article.
-
Transcobalamin I: a novel prognostic biomarker of neoadjuvant chemotherapy in locally advanced hypopharyngeal squamous cell cancers.Onco Targets Ther. 2018 Jul 24;11:4253-4261. doi: 10.2147/OTT.S166514. eCollection 2018. Onco Targets Ther. 2018. PMID: 30100732 Free PMC article.
-
The presence of risk factors and corresponding treatment strategies post-surgical resection in stage IV hypopharyngeal squamous cell carcinoma patients: a retrospective cohort study.Ann Transl Med. 2020 Mar;8(5):189. doi: 10.21037/atm.2020.01.102. Ann Transl Med. 2020. PMID: 32309336 Free PMC article.
References
-
- Hoffman HT, Karnell LH, Funk GF, Robinson RA, Menck HR. The National Cancer Data Base report on cancer of the head and neck. Arch Otolaryngol Head Neck Surg. 1998;124:951–962. - PubMed
-
- Hung S-K, Chen H-L, Hsieh C-H, Hsu W-L, Chang K-H, Liu D-W, Chen Y-J, Lee M-S. Treatment of advanced hypopharyngeal cancer-comparison of two modalities. Tzu Chi Med J. 2006;18:15–21.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources